Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

about

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

Item

http://www.wikidata.org/entity/Q54976764

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

@en

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

@nl

type

Item

label

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

@en

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

@nl

prefLabel

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

@en

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

@nl

P1476

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

@en

P2093

Brendan Pang

http://www.w3.org/2001/XMLSchema#string

Henry Yang

http://www.w3.org/2001/XMLSchema#string

Javier Cortés

http://www.w3.org/2001/XMLSchema#string

Marta Guzman

http://www.w3.org/2001/XMLSchema#string

Marta Palafox

http://www.w3.org/2001/XMLSchema#string

Nesaretnam Barr Kumarakulasinghe

http://www.w3.org/2001/XMLSchema#string

Nishi Kumari

http://www.w3.org/2001/XMLSchema#string

Patrick William Jaynes

http://www.w3.org/2001/XMLSchema#string

Zhou Siqin

http://www.w3.org/2001/XMLSchema#string

Zul Fazreen Bin Adam Isa

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin

The ubiquitin-specific protease USP28 is required for MYC stability

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

RNA-guided human genome engineering via Cas9

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

P304

1913-1928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20171960

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

215

http://www.w3.org/2001/XMLSchema#string

P50

Prasanna Vasudevan Iyengar

Azad Saei

John Lalith Charles Richard

Pieter J Eichhorn

Eva Muñoz-Couselo

Christopher Nötzel

P577

2018-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29880484

http://www.w3.org/2001/XMLSchema#string

P932

6028519

http://www.w3.org/2001/XMLSchema#string